Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
16 mai 2024 07h30 HE
|
Biogen Inc.
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
14 mai 2024 19h33 HE
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Biogen Reports Progress on Corporate Responsibility Priorities
02 mai 2024 07h30 HE
|
Biogen Inc.
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)...
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
25 avr. 2024 16h05 HE
|
Biogen Inc.
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE...
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
06 mars 2024 07h30 HE
|
Biogen Inc.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
04 mars 2024 16h15 HE
|
Biogen Inc.
New data advances understanding of new approaches to treating Alzheimer’s diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE...
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
23 févr. 2024 07h00 HE
|
Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
12 févr. 2024 16h06 HE
|
Biogen Inc.
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its...
Biogen to Realign Resources for Alzheimer's Disease Franchise
31 janv. 2024 07h30 HE
|
Biogen Inc.
Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer’s...
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
19 déc. 2023 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions...